Projects

FIW-2025-01-00000724”, titled “A Non-invasive, Point-of-Care, 2-in-1 IoT Device for the Estimation of Rifampicin and Bilirubin in Blood, for Therapeutic Drug Management of Tuberculosis in a Community Setting

Project Description

Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation. Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.

Project Duration

2026 - Ongoing

Project Lead

Dr. Mary Dias, Dr. Mamatha. V

Authors

Dr. Mary Dias, Dr. Mamatha. V

Project Status

ongoing

Project Type

ICMR